SCHEMBL2784944

SCHEMBL2784944

CCN1CCN(c2cccc(F)c2O)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
KDM4E B2RXH2 6/20 0.50
POLB P06746 1/20 0.50
TSHR P16473 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
GAA P10253 1/20 0.48
CHRNA7 P36544 1/20 0.46
MAPK1 P28482 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
HSD17B10 Q99714 2/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
KDM2B Q8NHM5 1/20 0.44
MAPT P10636 1/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5506136 0.93 DRD2 (0.52) ALDH1A1KDM4EPOLBTSHRTDP1
SCHEMBL2782272 0.88 DRD2 (0.56) ALDH1A1KDM4EPOLBTSHRTDP1
SCHEMBL4960473 0.86 CYP1A2 (0.50) ALDH1A1KDM4EPOLBTSHRTDP1
SCHEMBL2783743 0.83 DRD3 (0.53) ALDH1A1KDM4EPOLBTSHRTDP1
SCHEMBL8044642 0.83 KDM4E (0.65) ALDH1A1KDM4EPOLBTSHRTDP1
SCHEMBL2782981 0.82 ALDH1A1 (0.51) ALDH1A1KDM4EPOLBTSHRTDP1
SCHEMBL2781296 0.81 ALDH1A1 (0.49) ALDH1A1KDM4EPOLBTSHRTDP1
SCHEMBL2780977 0.81 KDM4E (0.50) ALDH1A1KDM4EPOLBTSHRTDP1
SCHEMBL2782686 0.81 DRD2 (0.55) ALDH1A1KDM4ECHRNA7RAB9ADRD2
SCHEMBL2784258 0.81 DRD2 (0.56) ALDH1A1KDM4EPOLBTSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2010-10-07 US claimed
EP-2204363-A1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2010-07-07 EP claimed
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2007-06-28 US claimed
US-8314126-B2 Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2012-11-20 US disclosed
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2010-10-07 US disclosed
US-7763639-B2 Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2010-07-27 US disclosed
EP-2204363-A1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2010-07-07 EP disclosed
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION SANIONA AB (DK) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256163-A1 DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, DRD4, DRD1 ALDH1A1 1194/4885KDM4E 1510/4885POLB 4493/4885
US-20070149542-A1 DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, DRD4, DRD1 ALDH1A1 1189/4885KDM4E 1739/4885POLB 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.